CN111040958A - Preparation method of fermentation product with multiple physiological function activities and special bacillus amyloliquefaciens thereof - Google Patents
Preparation method of fermentation product with multiple physiological function activities and special bacillus amyloliquefaciens thereof Download PDFInfo
- Publication number
- CN111040958A CN111040958A CN201811195573.9A CN201811195573A CN111040958A CN 111040958 A CN111040958 A CN 111040958A CN 201811195573 A CN201811195573 A CN 201811195573A CN 111040958 A CN111040958 A CN 111040958A
- Authority
- CN
- China
- Prior art keywords
- preparation
- fermented
- content
- bacillus amyloliquefaciens
- bean curd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000193744 Bacillus amyloliquefaciens Species 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- 238000000855 fermentation Methods 0.000 title claims abstract description 32
- 230000004151 fermentation Effects 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 title claims description 62
- 230000035790 physiological processes and functions Effects 0.000 title description 3
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 142
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 142
- 235000013527 bean curd Nutrition 0.000 claims abstract description 122
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 230000005764 inhibitory process Effects 0.000 claims abstract description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 20
- 229920001184 polypeptide Polymers 0.000 claims abstract description 19
- 230000014508 negative regulation of coagulation Effects 0.000 claims abstract description 16
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims abstract description 15
- 108010028144 alpha-Glucosidases Proteins 0.000 claims abstract description 15
- 230000003480 fibrinolytic effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 230000002401 inhibitory effect Effects 0.000 claims description 30
- 206010020772 Hypertension Diseases 0.000 claims description 28
- 229940012957 plasmin Drugs 0.000 claims description 28
- 230000001603 reducing effect Effects 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 101710196208 Fibrinolytic enzyme Proteins 0.000 claims description 20
- 229940088598 enzyme Drugs 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- -1 DPPH free radical Chemical class 0.000 claims description 15
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 15
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 15
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 14
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 14
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 14
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 12
- 229930003944 flavone Natural products 0.000 claims description 12
- 150000002212 flavone derivatives Chemical class 0.000 claims description 12
- 235000011949 flavones Nutrition 0.000 claims description 12
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 claims description 12
- 239000002068 microbial inoculum Substances 0.000 claims description 12
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 12
- 150000003254 radicals Chemical class 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 10
- 238000010025 steaming Methods 0.000 claims description 10
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 9
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 208000007536 Thrombosis Diseases 0.000 claims description 8
- 230000010100 anticoagulation Effects 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 238000009629 microbiological culture Methods 0.000 claims description 5
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 claims description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004373 acetylcholine Drugs 0.000 claims description 3
- 230000003064 anti-oxidating effect Effects 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000000643 oven drying Methods 0.000 claims description 3
- 108090000371 Esterases Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 102000004366 Glucosidases Human genes 0.000 claims description 2
- 108010056771 Glucosidases Proteins 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 claims 2
- 230000002000 scavenging effect Effects 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- 230000005714 functional activity Effects 0.000 abstract description 11
- 239000000047 product Substances 0.000 description 58
- 239000000284 extract Substances 0.000 description 41
- 239000000843 powder Substances 0.000 description 40
- 108010088842 Fibrinolysin Proteins 0.000 description 26
- 239000007788 liquid Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 230000001580 bacterial effect Effects 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 19
- 239000008176 lyophilized powder Substances 0.000 description 18
- 238000002156 mixing Methods 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 18
- 244000068988 Glycine max Species 0.000 description 17
- 235000010469 Glycine max Nutrition 0.000 description 17
- 244000046052 Phaseolus vulgaris Species 0.000 description 16
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 16
- 235000013305 food Nutrition 0.000 description 15
- 239000000523 sample Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 102000009123 Fibrin Human genes 0.000 description 11
- 108010073385 Fibrin Proteins 0.000 description 11
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 11
- 238000012258 culturing Methods 0.000 description 11
- 229950003499 fibrin Drugs 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000006286 aqueous extract Substances 0.000 description 9
- 102100033639 Acetylcholinesterase Human genes 0.000 description 8
- 238000010411 cooking Methods 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000012880 LB liquid culture medium Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 6
- 229960001008 heparin sodium Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000002137 ultrasound extraction Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 229960002632 acarbose Drugs 0.000 description 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000021107 fermented food Nutrition 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 229960005356 urokinase Drugs 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 3
- 229960000830 captopril Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000004328 sodium tetraborate Substances 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 235000012874 Phaseolus calcaratus Nutrition 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 241000219977 Vigna Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 235000013557 nattō Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- CHCOFDZSJYMQMX-NOQNJSOHSA-N (2s)-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]py Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)N)C(C)C)C1=CC=C(O)C=C1 CHCOFDZSJYMQMX-NOQNJSOHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241001358279 Malaya Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 235000010716 Vigna mungo Nutrition 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 108010083984 angiotensin A Proteins 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000011852 carbon nanoparticle Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 108010067471 inhibin A Proteins 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 108010078226 phenylalanine oxidase Proteins 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013548 tempeh Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000004562 water dispersible granule Substances 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
- 238000005491 wire drawing Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C20/00—Cheese substitutes
- A23C20/02—Cheese substitutes containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates
- A23C20/025—Cheese substitutes containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates mainly containing proteins from pulses or oilseeds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24072—Fibrolase (3.4.24.72)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Beans For Foods Or Fodder (AREA)
Abstract
The invention discloses a preparation method of a fermentation product with various physiological functional activities and a special Bacillus amyloliquefaciens thereof, wherein the preparation method comprises the steps of inoculating Bacillus amyloliquefaciens CAUNDJ118CGMCC No.16050 into sterile red beans or sterile bean curd, and fermenting to obtain the fermentation product, wherein compared with the sterile red beans or the sterile bean curd, the fibrinolytic activity and/or anticoagulant activity and/or α -glucosidase inhibition rate and/or total phenol content and/or polypeptide content of the fermentation product are obviously improved.
Description
Technical Field
The invention belongs to the field of fermentation, and particularly relates to a preparation method of a fermentation product with multiple physiological functional activities and a special bacillus amyloliquefaciens thereof.
Background
Thrombotic diseases are cardiovascular and cerebrovascular diseases that seriously threaten human health. It is statistically determined that thrombus blockage is an important factor in lethal disabling of thrombotic diseases (Lau et al Circulation Journal of the Japanese Circulation Society, 2017, 81: 920-. The current thrombolytic drugs for treating thrombotic diseases commonly used in clinic mainly comprise streptokinase, urokinase and tissue-type plasminogen activator (t-PA), however, most of these drugs have the disadvantages of high price, short half-life or easy bleeding (Wei et al. journal of agricultural and Food Chemistry, 2011, 59: 3957-. The exploration of safe and economic novel thrombolytic foods becomes one of the research hotspots at home and abroad in recent years.
Fermentation is a traditional processing technique that changes the physicochemical properties of food and enhances the functional activity of food. The application of fermentation technology is particularly extensive in asian regions. Asian people have low prevalence rate of thrombotic diseases, and the method is closely related to the frequent eating of fermented foods such as natto, fermented soybean, soybean paste and tempeh (Kotb. Springer briefs in Microbiology, 2012: 1-74). The use of microorganism fermentation of cereal beans not only eliminates anti-nutritional factors but also produces active ingredients and functional activities that cereal beans do not have originally (Chang et al food Chemistry, 2012, 133: 1611-. Bacillus is an important genus for producing plasmin activity. Sumi et al, Japan, isolated and extracted an active substance having an ability to efficiently dissolve fibrin from soybeans fermented with Bacillus subtilis (Sumi et al, Experientia, 1987, 43: 1110-1111). Jhan et al use Bacillus subtilis and Lactobacillus bulgaricus to ferment red beans in a mixed manner to obtain a fermented product with plasmin activity and enrich the probiotic species in the product (Jhan et al LWT-Food Science and Technology, 2015, 63: 1281) -1287.). Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) is a bacterium with high affinity with Bacillus subtilis, is generally present in fermented foods such as fermented soya beans or soybean paste and the like, and is widely applied as an antibacterial agent in the industries of food, feed and the like (Peng et al. comprehensive Biochemistry & Physiology B-Biochemistry & Molecular Biology, 2003, 134: 45-52; Chakraborty et al. food chemistry.2017, 218: 427-434; Liu Shi Zhe et al. A Bacillus amyloliquefaciens, an antibacterial agent prepared from the same and application thereof, Chinese patent application No. 201510330551.9). In recent years, the research on the preparation of plasmin by using bacillus amyloliquefaciens is gradually increased. Wang Xiao lan, etc. separates bacillus amyloliquefaciens producing plasmin from fermented soya beans, and the activity of the plasmin after liquid fermentation culture reaches 324.6-410.2IU/mL (Wang Xiao lan, etc., a fermented soya bean plasmin and its culture method, Chinese patent, application number: 201710320905.0). Although there are many reports on the utilization of the activity of Bacillus amyloliquefaciens to produce plasmin at home and abroad at present, the activity of the plasmin is mostly 100-3000IU/g (Gao Yang Xin et al, China brewing, 36: 58-62). The plasmin-producing activity level of bacillus utilized at home and abroad is still not high, and the plasmin-producing bacillus has less application in fermented foods.
Small red bean (Vigna umbellata), also known as small red bean, is sour and sour in taste, neutral in nature, non-toxic, and has the effects of inducing diuresis to alleviate edema, detoxifying and expelling pus, etc., and China is the world with the largest small red bean yield (Chenqiao, etc. Chinese patent medicine, 2017, 39: 1414 and 1422). The research finds that the small red beans are rich in essential amino acids, a plurality of unsaturated fatty acids, minerals and dietary fibers, and are functional food with high protein, low fat and multiple nutrients. The functional activity of small red beans in Vigna is higher than that of beans of other varieties (Bishtet al. genetic & Genomic Resources of gain Legend Improvement, 2013, 74: 237. 267.), which are rich in polyphenol, flavone and pigment, etc. (Yao et al. International Journal of molecular Sciences, 2012, 13: 2707. 2716). So far, small red bean processed products are few and are not fully developed and utilized (Pengxue et al. food industry science and technology, 2013, 34: 389-395). Research on the red bean peptide oral liquid with the effects of reducing blood pressure and blood sugar by fermenting red bean with aspergillus oryzae has been carried out, and no specific data are disclosed about the effects of reducing blood pressure and blood sugar (Zhangli et al. a method for preparing the red bean peptide oral liquid with the effects of reducing blood pressure and blood sugar by a fermentation method. Chinese patent application No. 201611146609.5). So far, no literature report and patent publication of the fibrinolytic enzyme activity produced by fermenting small red beans by utilizing bacillus amyloliquefaciens exist.
Bean curd is one of the traditional soybean products in China, and is a gel containing water, lipid and other components formed by extracting soybeans with water and coagulating protein with salt or acid. The bean curd contains abundant protein, and is a good source for obtaining high-quality protein. However, tofu is perishable and perishable due to its high moisture and high nutrition, and further has a short shelf life (Tian Qi & Hua Lian Fei. food and fat 2007, 137: 7-10). The fermentation can improve the storage property of food, and can also enhance the biological activities of raw materials such as oxidation resistance, obesity resistance, bacteria resistance and the like (the theory, university of south China, 2012, vector separation). Fermented bean curd with large consumption at home and abroad comprises Chinese fermented bean curd, stinky bean curd, Japanese Tofuyo, Tau ju in Malaya and the like, and the fermented food needs high salt content (4-14%) to inhibit the growth of harmful microorganisms in the fermentation process, and has a long fermentation period which is generally 3-6 months (Lioe et al food Chemistry, 2018, 252: 265. sup. 270.). So far, no research related to bean curd fermentation by using bacillus amyloliquefaciens exists.
Disclosure of Invention
The invention aims to provide a fermentation product with various physiological functional activities, and the fermentation product can be fermented small red beans or fermented bean curd.
In order to protect the Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118, the strain is preserved in China general microbiological culture Collection center (CGMCC for short, the address is No. 3 of Xilu No.1 of Beijing Kogyo-Yang district) in 2018, at the 03 th of 07 th and 03 th, and the preservation number is CGMCC No. 16050. Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118CGMCC No.16050 is simply called Bacillus amyloliquefaciens CAUNDJ 118.
The invention also protects a microbial inoculum which contains the bacillus amyloliquefaciens CAUNDJ 118.
The microbial inoculum can be used for preparing at least one of A) small red beans through fermentation culture, A) products with plasmin activity, A) products with anticoagulant activity, A) products with blood sugar reducing function, A) products with antioxidant activity, A) products for eliminating DPPH free radicals, A) products for eliminating ABTS free radicals, A) products for improving FRAP reducing power, A) products for improving glucosidase inhibiting power, A) products for improving DPP-IV inhibiting power, A) products for improving angiotensin converting enzyme inhibiting power, A) products for improving acetylcholine esterase inhibiting power, A) products for improving total phenol content, A) products for improving flavone content, A) products for improving polypeptide content, A) products for improving SOD enzyme content, A) products for preventing and/or treating cardiovascular and cerebrovascular diseases, A) products for preparing products for preventing and/or treating thrombotic diseases, A) products for improving thrombocyte inhibiting power and/or treating hypertension, A) products for improving DPP-IV inhibiting power, A) products for improving DPP-A inhibiting power and/or treating hypertension, A) products for improving DPP-IV inhibiting power, A) products for improving free radical inhibiting power and/or treating diabetes mellitus, A) products for improving free radical inhibiting power, A) products for treating or preventing hypertension and/or treating diabetes mellitus, A) products for improving hypertension and/or treating hypertension, and/or treating senile dementia, A) products for improving free radical inhibiting power, and/or improving DPP-IV, and/or preventing hypertension, A) products for treating hypertension, and/or treating hypertension, and/or improving hypertension, and/or treating hypertension, or improving hypertension, and/or treating hypertension, or improving hypertension, and/or preventing hypertension, or treating hypertension, and/or treating hypertension, or improving hypertension, or treating hypertension, and/or treating hypertension.
The invention also provides a preparation method of the microbial inoculum, which comprises the following steps: inoculating the bacillus amyloliquefaciens CAUNDJ118 to a bacterial culture medium and culturing to obtain a bacterial liquid, namely the microbial inoculum.
The bacterial culture medium can be LB liquid culture medium. The preparation method of the LB liquid culture medium can be specifically as follows: dissolving 10g of peptone, 10g of sodium chloride and 5g of yeast powder in deionized water, and then using the deionized water to fix the volume to 1L; sterilizing at 121 deg.C for 15 min.
In the preparation method of the microbial inoculum, the specific culture conditions can be as follows: 35-39 deg.C (such as 35-37 deg.C, 37-39 deg.C, 35 deg.C, 37 deg.C or 39 deg.C), 100-300rpm (such as 100-200rpm, 200-300rpm, 100rpm, 200rpm or 300rpm), and culturing for 10-20h (such as 10-15h, 15-20h, 10h, 15h or 20h) with shaking.
The microbial inoculum may include a carrier in addition to the active ingredient. The carrier may be a solid carrier or a liquid carrier. The solid carrier may be a mineral material, a plant material or a polymeric compound. The mineral material may be at least one of clay, talc, kaolin, montmorillonite, white carbon, zeolite, silica, and diatomaceous earth. The plant material may be at least one of corn flour, bean flour and starch. The high molecular compound may be polyvinyl alcohol and/or polyglycol. The liquid carrier can be an organic solvent, vegetable oil, mineral oil, or water. The organic solvent may be decane and/or dodecane. In the microbial inoculum, the active ingredient may be present in the form of cultured living cells, a fermentation broth of living cells, a filtrate of a cell culture, or a mixture of cells and a filtrate. The composition can be prepared into various dosage forms, such as liquid, emulsion, suspending agent, powder, granules, wettable powder or water dispersible granules.
According to the requirement, the microbial inoculum can also be added with a surfactant (such as Tween 20, Tween 80 and the like), a binder, a stabilizer (such as an antioxidant), a pH regulator and the like.
The invention also discloses application of the bacillus amyloliquefaciens CAUNDJ118 or any microbial inoculum described above, which can be at least one of A1) -A43), A1) fermentation culture of small red beans, A2) preparation of products with fibrinolytic enzyme activity, A3) preparation of products with anticoagulant activity, A4) preparation of products with blood sugar reducing function, A5) preparation of products with antioxidant activity, A6) preparation of products for eliminating DPPH free radicals, A7) preparation of products for eliminating ABTS free radicals, A8) preparation of products for improving FRAP reducing power, A8) preparation of products for improving 8-glucosidase rate, A8) preparation of products for improving DPP-IV inhibiting rate, A8) preparation of products for improving angiotensin converting enzyme inhibiting rate, A8) preparation of products for improving angiotensin A inhibiting enzyme inhibiting rate or improving angiotensin A8) inhibiting rate, B-A activity, B-8) preparation of products for preparing products for improving, A8) preparation of products for improving, 8) for improving angiotensin-B-8) for improving, 8) preparation of products for improving angiotensin-B-8) for treating, or 8) for treating diabetes mellitus, or 8) for treating or improving blood glucose-B-8) for treating diabetes mellitus, or improving blood sugar-8) treating diabetes mellitus, or improving blood glucose-8) for treating diabetes mellitus, or improving blood glucose-8) treating diabetes mellitus, or improving blood sugar-8) treating diabetes mellitus, or improving total-8) treating diabetes mellitus, or improving blood sugar-8) treating diabetes mellitus, or improving blood-8.
In the application, the product can be functional food, health-care product and medicine.
In the above application, the product may be fermented red bean or fermented bean curd prepared by any one of the following methods.
The invention also provides a preparation method of the fermented red bean, which comprises the steps of inoculating bacillus amyloliquefaciens into the sterile red bean, and fermenting to obtain the fermented red bean, wherein compared with the sterile red bean, the fibrinolytic enzyme activity and/or the anticoagulant activity and/or the antioxidant activity and/or the DPPH free radical clearance rate and/or the ABTS free radical clearance rate and/or the FRAP reducing power and/or α -glucosidase inhibition rate and/or the DPP-IV inhibition rate and/or the total phenol content and/or the flavone content and/or the polypeptide content and/or the SOD enzyme content of the fermented red bean are improved (obviously improved).
In the method, the steps for preparing the sterile small red beans can be as follows: soaking semen Phaseoli in water, and steaming for 20-40min (such as 20-30min, 30-40min, 20min, 30min or 40 min).
The time for soaking the small red beans can be more than 9 hours.
The soaking time of semen Phaseoli is 9-12h (such as 9-11h, 11-12h, 9h, 11h or 12 h).
The temperature for soaking semen Phaseoli can be 22-30 deg.C (such as 22-25 deg.C, 25-30 deg.C, 22 deg.C, 25 deg.C or 30 deg.C).
The small red bean is soaked in water, and the soaking degree can be as follows: the wet weight of the soaked small red beans is 2.5 +/-0.5 times of that of the small red beans before soaking.
In the method, the inoculation amount of the bacillus amyloliquefaciens for inoculating the sterile small red beans can be 105-107CFU/100g (e.g., 10)5-106CFU/100g、106-107CFU/100g、105CFU/100g、106CFU/100g or 107CFU/100g) sterile red bean.
The invention also provides a preparation method of the fermented bean curd, which comprises the steps of inoculating the bacillus amyloliquefaciens into the sterile bean curd, and fermenting to obtain the fermented bean curd, wherein compared with the sterile bean curd, the fibrinolytic enzyme activity and/or the anticoagulation activity and/or the acetylcholinesterase inhibition rate and/or the angiotensin converting enzyme inhibition rate and/or the α -glucosidase inhibition rate and/or the total phenol content and/or the polypeptide content of the fermented bean curd are improved (obviously improved).
In the above method, the step of preparing the sterilized bean curd may be: oven drying bean curd, and steaming for 10-40min (such as 10-20min, 20-30min, 30-40min, 10min, 20min, 30min or 40 min).
The drying temperature can be 25-40 deg.C (such as 25-30 deg.C, 30-40 deg.C, 25 deg.C, 30 deg.C or 40 deg.C)
The degree of drying may be: the water content of the bean curd block is more than 55%.
The degree of drying may specifically be: the moisture content of the bean curd block is 55-85% (m/m) (such as 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 55%, 60%, 65%, 70%, 75%, 80%, or 85%).
The protein content of the bean curd can be more than 5% (m/m). The water content of the bean curd is 70-90%.
The protein content of the bean curd may be 5-10% (m/m) (e.g. 5-8%, 8-10%, 5%, 8% or 10%).
The bean curd can be commercially available bean curd (raw materials can be common beans such as soybean, soybean and the like), and can also be prepared by using common beans (such as soybean, mung bean, small red bean and the like) as raw materials.
The bean curd can be cut into bean curd blocks firstly, and then the bean curd blocks are dried.
The length, width and height of the bean curd block can be more than 2 cm.
The length, width and height of the bean curd block can be 2-5cm (such as 2-3cm, 3-4cm, 4-5cm, 2cm, 3cm, 4cm or 5 cm).
In the above method, the inoculation amount of the "inoculating Bacillus amyloliquefaciens into sterile bean curd" may be 107-109CFU/100g (e.g., 10)7-108CFU/100g、108-109CFU/100g、107CFU/100g、108CFU/100g or 109CFU/100g) sterilized bean curd.
In any of the above methods, the cooking temperature may be 95-121 deg.C (e.g., 95-110 deg.C, 121 deg.C, 95 deg.C, 110 deg.C, or 121 deg.C).
In any of the above methods, the fermentation may specifically be performed at 35-40 deg.C (e.g., 35-37 deg.C, 37-40 deg.C, 35 deg.C, 37 deg.C or 40 deg.C) for 24-48h (e.g., 24-36h, 36-48h, 24h, 36h or 48 h).
In any of the above methods, the Bacillus amyloliquefaciens may specifically be Bacillus amyloliquefaciens CAUNDJ 118.
The invention also protects K1) or K2).
K1) The application of the fermented red bean prepared by any one of the methods can be at least one of A22), A22) for producing plasmin, A22) for anticoagulation, A22) for reducing blood sugar, A22) for antioxidation, A22) for eliminating DPPH free radicals, A22) for eliminating ABTS free radicals, A22) for improving the reducing power of FRAP, A22) for improving 22-glucosidase inhibition rate, A22) for improving DPP-IV inhibition rate, A22) for improving total phenol content, A22) for improving flavone content, A22) for improving polypeptide content, A22) for improving the enzyme content, A22) for treating a cardiovascular disease or preventing a diabetic disease, and/or treating a diabetic/diabetic disease.
K2) The fermented bean curd prepared by any one of the methods can be at least one of A22), A23), A24), A29), A31), A32), A33), A35), A37), A38), A39), 40), 41) and A43), wherein A22) produces plasmin, A23) anticoagulation, A24) reduces blood sugar, A29) improves α -glucosidase inhibition rate, A31) improves angiotensin converting enzyme inhibition rate, A32) improves acetylcholine esterase inhibition rate, A33) improves total phenol content, A35) improves polypeptide content, A37) prevents and/or treats cardiovascular and cerebrovascular diseases, A38) prevents and/or treats thrombotic diseases, A39) prevents and/or treats diabetes, 40) prevents and/or treats hypertension, 41) prevents and/or treats senile 43) and reduces senile dementia.
Experiments prove that the plasmin activity of the fermented red bean prepared by the method provided by the invention is as high as 78.0FU/g wet weight (4890.0IU/g wet weight) and 220FU/g dry weight (13814IU/g dry weight), compared with the unfermented red bean, the anticoagulant activity, the antioxidant activity, the α -glucosidase inhibition rate and the DPP-IV inhibition rate of the fermented red bean are all obviously improved, the total phenol content, the flavone content, the polypeptide content and the SOD enzyme content are also obviously improved, the fermented red bean has the effects of reducing blood sugar and resisting blood coagulation, and has great application value in developing products for preventing and/or treating cardiovascular and cerebrovascular diseases and/or diabetes.
Drawings
FIG. 1 shows the effect of cooking time on the viscosity (▲), firmness (●) and plasmin activity (■) of B.amyloliquefaciens fermented red beans.
FIG. 2 shows the effect of inoculum size on the viscosity (▲), firmness (●) and plasmin activity (■) of B.amyloliquefaciens fermented red beans.
FIG. 3 is a graph showing the effect of fermentation time on the viscosity (▲), firmness (●) and plasmin activity (■) of B.amyloliquefaciens fermented red beans.
FIG. 4 shows DPP-IV inhibitory effects of unfermented red bean (▲) and fermented red bean (●), in which (■) is a positive control, statin A.
FIG. 5 shows the α -glucosidase inhibitory effect of unfermented red bean (▲) and fermented red bean (●), in which (◆) is the positive control acarbose.
FIG. 6 shows the anticoagulant activity of unfermented red bean (▲) and fermented red bean (●), in which (×) is the positive control heparin sodium.
Deposit description
The strain name is as follows: bacillus amyloliquefaciens
Latin name: bacillus amyloliquefaciens
The strain number is as follows: CAUNDJ118
The preservation organization: china general microbiological culture Collection center
The preservation organization is abbreviated as: CGMCC (China general microbiological culture Collection center)
Address: xilu No.1 Hospital No. 3 of Beijing market facing Yang district
The preservation date is as follows: year 2018, month 07, 03
Registration number of the preservation center: CGMCC No.16050
Detailed Description
The following examples are given to facilitate a better understanding of the invention, but do not limit the invention. The experimental procedures in the following examples are conventional unless otherwise specified. The test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified. The quantitative tests in the following examples, all set up three replicates and the results averaged.
The following examples were carried out using the fibrin plate method for detecting plasmin activity as follows:
a clean culture dish is taken, and 5mL of 1% (w/v) agarose aqueous solution, 5mL of 0.6% (w/v) fibrinogen solution (solvent is pH8.0, 50mmol/L borax buffer solution) and 100 μ L of thrombin (concentration is 10U/mL) are added into each culture dish and mixed uniformly. After it is cooled (i.e. fibrin plate), the plate is perforated uniformly with a hole puncher, the hole diameter is 3mm, and the residual water in the hole is sucked dry. 10 μ L of the sample was added to the wells, incubated at 37 ℃ for 18h, and the diameter of the transparent circle was measured using an electronic ruler using a cross method.
And (3) drawing a standard curve by taking urokinase as a standard substance: with urokinase fibrinolytic enzyme activity (IU/mL): 20. 40, 60, 80, 100 and 200, 400, 600, 800 and 1000 are vertical coordinates, the area of a transparent ring is horizontal coordinates, two urokinase standard curves with different concentration series are respectively drawn, and the equivalent of the fibrinolytic enzyme activity of the sample is calculated according to a standard regression equation, wherein the unit IU/g wet bean.
The following examples were carried out using the fibrinolysis method to detect the fibrinolytic enzyme activity as follows:
adding 1.4mL of pH8.0 and 50mmol/L borax buffer solution and 0.4mL of 0.72% (w/v) fibrinogen solution (the solvent is pH8.0 and 50mmol/L borax buffer solution) into a test tube, uniformly mixing, preheating in a water bath kettle at 37 ℃ for 5min, adding 0.1mL of thrombin (the concentration is 20U/mL), uniformly mixing, and reacting at 37 ℃ for 10min to solidify. Adding 0.1mL of sample, mixing uniformly, reacting at 37 ℃ for 60min, and shaking and mixing uniformly every 20 min. Immediately after the reaction, 2.0mL of a 0.2M trichloroacetic acid solution (terminator) was added, the mixture was centrifuged at 10000rpm for 10min, and the supernatant was collected to determine the absorbance at 275 nm.
Definition of Activity: the amount of enzyme required for an increase in absorbance at 275nm per minute of 0.01 localizes the fibrin degrading enzyme activity (FU) of 1 unit.
The calculation formula is as follows: x is (Ar-Ac). times.N/(60X 0.01X 0.1), wherein X represents the plasmin activity (FU/mL), Ar represents the absorbance of the sample, Ac represents the absorbance of the control, 60 represents the reaction time 60min, and 0.1 represents 0.1mL of the enzyme solution participating in the reaction, measured in 1 min. N represents the dilution factor.
The procedure for determining hardness in the following examples is as follows:
the small red bean sample was taken out from the refrigerator at 4 ℃ and left to stand at room temperature, and the hardness was measured by a texture analyzer. The test method comprises the following steps: 25000g of load unit and TA 4/100038.1-mm D of probe, 3 small red bean samples are parallelly placed, the compression deformation amount is 60%, the trigger point load is 5g, the testing speed is 1mm/s, each sample is parallelly tested for 6 times, and the average value is taken.
The procedure for determining the viscosity in the following examples is as follows:
taking 10g of small red bean sample, adding 100mL of distilled water, shaking and extracting for 30min, centrifuging at 10000rpm for 20min, collecting supernatant, and measuring viscosity at 30 ℃.
LB liquid medium: dissolving 10g of peptone, 10g of sodium chloride and 5g of yeast powder in deionized water, and then using the deionized water to fix the volume to 1L; sterilizing at 121 deg.C for 15 min.
LB solid medium: dissolving 10g of peptone, 10g of sodium chloride, 5g of yeast powder and 7g of agar in deionized water, and then fixing the volume to 1L by using the deionized water; sterilizing at 121 deg.C for 15 min.
LB solid plate: and pouring the LB solid culture medium with the temperature of about 55 ℃ into a sterile culture dish, and cooling to obtain an LB solid plate.
Methods for determining total phenol content and flavone content are described in the following documents: yao, Y., Cheng, X.Z., Wang, L.X., Wang, S.H., & Ren, G. (2012). Major phenolic compounds, antioxidant capacity and antibiotic beta potential of a rice bean (Vigna umbellate L.). International Journal of Molecular Sciences, 13, 2707-.
Methods for determining the content of polypeptides are described in the following documents: zhang, b., Sun, q., Liu, h.j., Li, s.z., & Jiang, Z.Q. (2017.) the mutation of action from Chinese customers and matters applications in the medium termination and production of antibiotic i-converting enzyme (ACE) inhibition peptides lwt-Food Science and technology, 78, 1-7.
Methods for determining the SOD enzyme content are described in the following documents: dong, D, Yin, L, Qi, Y, Xu, L, & Peng, J. (2015). Protective effect of the total saponin from a rock strain of microxfrouit against carbon nanoparticles, 7(6), 4829.
Methods for determining the reducing sugar content are described in the following documents: sritongtae, B., Sangsukiam, T., Morgan, M.R., & Duangmal, K. (2017). Effect of acid prediction and simulation on the composition and antibiotic activity of edge bean (Vigna umbellata). Food Chemistry, 227, 280-.
Methods for determining DPPH radical clearance, ABTS radical clearance and FRAP reduction are described in the following documents: dudonn, S., Vitrac, X., Courtere, P., Wolinez, M., & M rillon, J.M. (2009).
Example 1 isolation, identification and preservation of Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118CGMCCNo.16050
Isolation of the bacterium CAUNDJ118
1. Adding 1g of commercially available Lentinus Edodes sauce into 10mL LB liquid culture medium, mixing, and culturing at 37 deg.C and 200rpm for 12 hr to obtain enrichment solution.
2. After the step 1 is completed, the enrichment solution is taken and added into a sterile test tube filled with 9mL of sterile physiological saline to be fully and uniformly mixed (the dilution is marked as 10-1) Then sucking 1mL of the mixture from the test tube, adding the mixture into another sterile test tube containing 9mL of sterile physiological saline, and uniformly mixing, and so on to obtain 10-2、10-3、10-4、10-5Bacterial suspensions of various dilutions. 0.1mL of each dilution was uniformly spread on an LB solid plate, 37Standing at constant temperature for 24 h.
3. And (3) after the step 2 is completed, selecting the colonies, and streaking the colonies on an LB solid plate to obtain single colonies.
4. And (3) respectively inoculating the single colonies obtained in the step (3) to an LB liquid culture medium, and culturing at 37 ℃ and 200rpm for 12h to obtain a culture bacterial liquid.
5. Dongnong 690 (hereinafter abbreviated as "Xiao-jin") was collected and soaked in water for 12 hours.
6. Inoculating the small-particle soybeans obtained in the step 5 with the culture solution obtained in the step 4 (the inoculation amount is 10 percent)7CFU/100g), mixing, fermenting and culturing at 40 deg.C for 24 hr, and after-ripening at 4 deg.C for 24 hr to obtain fermented semen glycines. The degree of stringiness and odor of each fermented soybean was recorded and fibrinolytic activity was measured by the fibrin plate method.
7. And (6) after the step 6 is finished, taking fermented soybeans which have natto flavor and high wire drawing degree and generate larger transparent rings on a fibrin flat plate, and detecting the activity of fibrinolytic enzyme by adopting a fibrin degradation method.
The single colony corresponding to the fermented soybean with higher plasmin activity is repeatedly confirmed for 3-5 times and named as bacterium CAUNDJ 118.
Identification of the bacterium CAUNDJ118
The isolated and purified bacterium CAUNDJ118 was identified in several ways:
1. morphological identification
The single colony status of the bacteria CAUNDJ118 growing on the LB solid plate was observed, and mainly included the color, transparency, wettability, colony surface status (smooth, protruding, wrinkled, dented, etc.), and colony edge status (neat, irregular, radial, etc.) of the colonies.
The result shows that the colony surface of the bacterium CAUNDJ118 separated and purified in the first step is round, slightly convex, milky yellow, semitransparent and sticky after being picked up; the colony is smooth and moist when young, and the colony edge is irregular and has the fold after the maturity.
Microscopic observation revealed that the bacterial bodies of CAUNDJ118 were in the form of short rods.
2. Physiological and biochemical characteristic analysis
The physiological and biochemical characteristics of the above-mentioned bacterium CAUNDJ118 were determined with reference to "Manual of identification of common bacterium System" (Dongxu bead, Chuia Miaoying. Manual of identification of common bacterium System. Beijing: scientific Press, 2011.) and "microbiological experiments" (Shenping, Fangxiu capacity, Liguanwu. microbiological experiments (third edition); Beijing: advanced education Press, 1999.).
The physiological and biochemical characteristics of the bacterium CAUNDJ118 are as follows: gram-positive bacteria, positive starch hydrolysis, positive gelatin liquefaction test, positive lecithin enzyme, negative phenylalanine dehydrogenase, positive V-P test and negative M.R enzyme, and can utilize glucose, sucrose, lactose, D-xylose and L-arabinose.
3. 16S rDNA sequence analysis
The isolated and purified bacterium CAUNDJ118 obtained in one of the above steps was cultured by a conventional method, the total DNA of the strain was extracted and used as a template, and the DNA sequence of the bacterium 16S rDNA universal primer 27 f: 5'-AGAGTTTGATCCTGGCTCAG-3' and 1492 r: 5'-GGTTACCTTGTTACGACTT-3' PCR amplification is carried out to obtain PCR amplification product. Reaction procedure: pre-denaturation at 95 ℃ for 5 min; denaturation at 95 ℃ for 30s, annealing at 51 ℃ for 45s, extension at 72 ℃ for 1.5min, and 30 cycles; extension at 72 ℃ for 10 min.
The PCR amplification product was subjected to sequencing by Biotechnology Ltd of Bomaide, Beijing. And carrying out gene comparison analysis on the sequencing result, and constructing a phylogenetic tree by using MEGA 5.0. Gene comparison was done online using the national center for Biotechnology information NCBI database (http:// www.ncbi.nlm.nih.gov).
The 16S rDNA sequence of the bacterium CAUNDJ118 is shown as a sequence 1 in a sequence table. Phylogenetic trees were constructed by MEGA5.0 software, showing that the bacterium CAUNDJ118 belongs to Bacillus amyloliquefaciens (Bacillus amyloliquefaciens).
The bacterium CAUNDJ118 isolated and purified in step one was identified as Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) in view of the above morphological characteristics, physiological and biochemical characteristics analysis and 16S rDNA sequence analysis. The bacterium CAUNDJ118 has been deposited in China general microbiological culture Collection center (CGMCC, address: No. 3 Xilu No.1 Beijing, Chaoyang, China) in 2018, No. 07/03, and the deposition number is CGMCC No. 16050. The bacterium CAUNDJ118 is called Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118CGMCC No.16050, and is called Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118 for short.
Example 2 Effect of cooking time, inoculum size and fermentation time on the viscosity, firmness and plasmin Activity of Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118 fermented Red Bean
Preparation of bacterial liquid
1. Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118 was inoculated into LB solid medium and cultured at 37 ℃ for 12 hours (for activation).
2. And (3) inoculating the single colony obtained in the step (1) to a10 mLLB liquid culture medium, and culturing at 37 ℃ and 200rpm to obtain a bacterial liquid.
Second, red bean pretreatment
1. Soaking semen Phaseoli in water at 25 deg.C for 9-12 hr to obtain soaked semen Phaseoli.
The wet weight of the soaked red bean is 2.5 +/-0.5 times of that of the red bean before soaking.
2. And (3) after the step (1) is finished, taking the soaked beans, and removing the soaked beans which are incomplete and/or uneven in color and/or poor in water absorption to obtain selected soaked beans.
3. After the step 2 is finished, selecting the selected soaked beans, steaming at 121 ℃ under high pressure for 10, 20, 30, 35, 40, 45 or 50min, and then cooling to 30-40 ℃ to obtain the unfermented small red beans.
Thirdly, fermentation
Inoculating the unfermented red bean obtained in the step two with the bacterial liquid obtained in the step one (the inoculation amount is 10)5CFU/100g、106CFU/100g、107CFU/100g、108CFU/100g or 109CFU/100g), mixing well, fermenting and culturing at 40 ℃ for 6h, 12h, 18h, 24h, 30h or 36h to obtain the fermented red bean.
Fourthly, detecting the fibrinolytic enzyme activity, hardness and viscosity of the fermented small red beans
Taking fermented red bean, and detecting the fibrinolytic enzyme activity by adopting a fibrin degradation method and a fibrin plate method respectively.
Taking fermented small red beans, and measuring hardness and viscosity.
The results show that the hardness of the fermented red bean is decreased and the viscosity and the plasmin activity are increased along with the increase of the cooking time. When the inoculation amount is 105When CFU/100g and fermentation time are 24h, the fibrinolytic enzyme activity, hardness and viscosity of the fermented small red beans are shown in figure 1; the cooking time is 40min, the fibrinolytic enzyme activity of the fermented red bean is highest and reaches 73.7FU/g wet weight. When the fermentation time is 24h and the cooking time is 40min, the fibrinolytic enzyme activity, hardness and viscosity of the fermented red bean are shown in figure 2; the inoculation amount is 107CFU/100g (namely the inoculation amount is logCFU/100g and is 7), the fibrinolytic enzyme activity of the fermented small red beans is the highest and reaches 78.0FU/g wet weight. When the inoculation amount is 107When CFU/100g and cooking time is 40min, the fibrinolytic enzyme activity, hardness and viscosity of the fermented red bean are shown in figure 3; the fermentation time is 24 hours, the plasmin activity of the fermented red bean is the highest, the plasmin activity detected by a fibrin degradation method is 78.0FU/g wet weight (220FU/g dry weight), and the plasmin activity detected by a fibrin plate method is 4890.0IU/g wet weight (13814IU/g dry weight).
Example 3 analysis of active ingredients and functional Activity of Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118 fermented red Bean
Preparation of bacterial liquid
1. Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118 was inoculated into LB solid medium and cultured at 37 ℃ for 12 hours (for activation).
2. And (3) inoculating the single colony obtained in the step (1) to a10 mLLB liquid culture medium, and culturing at 37 ℃ and 200rpm for 12h to obtain a bacterial liquid.
3. Adding LB liquid culture medium into the bacterial liquid obtained in the step 2 for dilution to obtain the bacterial liquid with the concentration of 107CFU/100g of bacterial liquid.
Second, red bean pretreatment
1. Soaking semen Phaseoli in water at 25 deg.C for 9-12 hr to obtain soaked semen Phaseoli.
The wet weight of the soaked red bean is 2.5 +/-0.5 times of that of the red bean before soaking.
2. And (3) after the step (1) is finished, taking the soaked beans, and removing the soaked beans which are incomplete and/or uneven in color and/or poor in water absorption to obtain selected soaked beans.
3. After the step 2 is finished, selecting the selected soaked beans, steaming at 121 ℃ for 40min under high pressure, and then cooling to 30-40 ℃ to obtain the unfermented small red beans.
Thirdly, fermentation
Inoculating the bacterial liquid obtained in the first step with the unfermented small red beans, wherein the inoculation amount is 107Mixing with CFU/100g, fermenting and culturing at 40 deg.C for 24 hr to obtain fermented semen Phaseoli.
Analysis of active ingredients
1. Measuring total phenol content, flavone content, polypeptide content and SOD enzyme content
(1) Mixing 1 volume part of fermented red bean with 5 volume parts of water, performing ultrasonic extraction for 3 times (ultrasonic parameters: 100W, 20min), centrifuging at 4000rpm for 10min, and collecting supernatant 1. Mixing 1 volume part of fermented red bean with 5 volume parts of 80% (v/v) ethanol water solution, performing ultrasonic extraction for 3 times (ultrasonic parameters: 100W, 20min), centrifuging at 4000rpm for 10min, and collecting supernatant 2.
(2) And (3) taking the supernatant fluid 1, and performing rotary evaporation and concentration to obtain a water extract of the fermented small red beans. And (3) taking the supernatant 2, and performing rotary evaporation and concentration to obtain an alcohol extract of the fermented small red beans.
(3) And (3) taking the water extract of the fermented small red beans or the alcohol extract of the fermented small red beans, and measuring the total phenol content, the flavone content, the polypeptide content and the SOD enzyme content.
2. Taking fermented small red beans, and measuring hardness and viscosity.
3. Determination of reducing sugar content
Taking fermented small red beans, and measuring the content of reducing sugar.
4. Determination of the moisture content
Taking fermented small red beans, and determining the moisture content according to GB/T5009.3-2010.
Replacing the fermented red bean with unfermented red bean according to the above steps, and using the rest steps as a control.
The results are shown in Table 1.
The results show that compared with the unfermented red bean, the total phenol content, the flavone content, the polypeptide content and the SOD enzyme content in the fermented red bean are respectively improved by 3.3 times, 1.5 times, 5.1 times and 4.8 times, the hardness is obviously reduced, and the viscosity, the reducing sugar content and the water content are all obviously improved.
TABLE 1 physicochemical Properties of fermented and unfermented red beans
Note that a, b are different, which indicates that the difference between groups is significant, and p is less than 0.05; GAE, gallic acid equivalent.
Fifth, analysis of functional Activity
1. Preparation of fermented red bean freeze-dried powder and unfermented red bean freeze-dried powder
Placing the unfermented red bean in a refrigerator at-20 deg.C for freezing for 24h, transferring to a vacuum freeze drier (cold trap temperature is-48 deg.C-60 deg.C), and freeze drying for 35-40h to obtain unfermented red bean lyophilized powder.
Freezing the fermented red bean in a refrigerator at-20 deg.C for 24h, transferring to a vacuum freeze drier (cold trap temperature is-48 deg.C to-60 deg.C), and freeze drying for 35-40h to obtain fermented red bean lyophilized powder.
2. Antioxidant activity of fermented red bean
The antioxidant activity is mainly reflected in DPPH free radical clearance rate, ABTS free radical clearance rate and FRAP reducing power.
(1) Mixing 1 volume part of fermented red bean lyophilized powder and 5 volume parts of water, performing ultrasonic extraction for 3 times (ultrasonic parameters: 100W, 20min), centrifuging at 4000rpm for 10min, and collecting supernatant 1. Mixing 1 volume part of fermented red bean lyophilized powder and 5 volume parts of 80% (v/v) ethanol water solution, performing ultrasonic extraction for 3 times (ultrasonic parameters: 100W, 20min), centrifuging at 4000rpm for 10min, and collecting supernatant 2.
(2) And (3) taking the supernatant fluid 1, and performing rotary evaporation and concentration to obtain a water extract of the fermented small red beans. And (3) taking the supernatant 2, and performing rotary evaporation and concentration to obtain an alcohol extract of the fermented small red beans.
(3) And (3) taking the water extract of the fermented small red beans or the alcohol extract of the fermented small red beans, and measuring DPPH free radical clearance rate, ABTS free radical clearance rate and FRAP reducing power.
Replacing the fermented red bean with unfermented red bean according to the steps, and obtaining the DPPH free radical clearance, ABTS free radical clearance and FRAP reducing power of the water extract or the alcohol extract of the unfermented red bean without changing other steps.
The results are shown in Table 2.
The results show that compared with the unfermented red bean, the DPPH free radical clearance rate, ABTS free radical clearance rate and FRAP reducing power in the fermented red bean are obviously improved, which indicates that the fermented red bean has higher antioxidant activity.
TABLE 2 antioxidant action of unfermented and fermented red beans
Note that a, b, c, d show significant differences between groups, p < 0.05.
3. Hypoglycemic effect of fermented small red beans
(1) The DPP-IV inhibition ratio of samples to be tested (fermented red bean lyophilized powder of different concentrations, unfermented red bean lyophilized powder of different concentrations or dipeptide inhibin A) was determined according to the method described in the literature (Wang, T.Y., Hsieh, C.H., Hung, C.C., Jao, C.L., Lin, P.Y., & Hsieh, Y.L., et al (2017). A study to estimate the potential of peptide-IV inhibitor activity in vitamin A. food Chemistry, 234, 431 and 438). Aprotinin a was a positive control.
The results of the experiment are shown in FIG. 4. The result shows that the DPP-IV inhibition rate of the fermented small red bean freeze-dried powder is obviously higher than that of the unfermented small red bean. When the concentrations of the fermented red bean freeze-dried powder and the unfermented red bean freeze-dried powder are both 6.4mg/mL, the DPP-IV inhibition rate (65.6%) of the fermented red bean freeze-dried powder is 2.2 times of that of the unfermented red bean.
(2) α -glucosidase inhibition rate of red bean samples to be tested (fermented red bean lyophilized powder of different concentration, unfermented red bean lyophilized powder of different concentration or acarbose) was detected as positive Control according to the method described in the literature (Shukla, s., Park, j., Kim, d.h., Hong, s.y., Lee, j.s., & Kim, M. (2016) (Total phenolic content, antioxidant, tyrosinase and α -glucopyranoside extraction of soluble mutant consumer enzyme, food Control, 59, 854-one 861.).
The experimental result is shown in figure 5. the result shows that the α -glucosidase inhibition rate of the fermented red bean freeze-dried powder is obviously higher than that of the unfermented red bean, and when the concentrations of the fermented red bean freeze-dried powder and the unfermented red bean freeze-dried powder are both 11.2mg/mL, the α -glucosidase inhibition rate (88.9%) of the fermented red bean freeze-dried powder is 3.2 times of that of the unfermented red bean.
The results show that the fermented small red beans have the function of reducing blood sugar.
4. Anticoagulant activity of fermented small red beans
The anticoagulant activity of the samples to be tested (freeze-dried powder of fermented red bean at different concentrations, freeze-dried powder of unfermented red bean at different concentrations or heparin sodium) was tested according to the method described In the literature (Zhang, S.B, (2016). Heparin sodium was the positive control.
The results of the experiment are shown in FIG. 6. The result shows that the anticoagulant activity of the fermented small red bean freeze-dried powder is obviously higher than that of the unfermented small red bean. When the concentrations of the fermented red bean freeze-dried powder and the unfermented red bean freeze-dried powder are both 1.0mg/mL, the anticoagulant activity (98.2%) of the fermented red bean freeze-dried powder is 15.6 times of that of the unfermented red bean and is 1.7 times of that of heparin sodium. Therefore, the fermented small red beans have good anticoagulant activity.
Example 4 analysis of active ingredients and functional Activity of Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118 fermented Bean curd
The tofu in this example is commercially available, and the raw material for processing tofu is soybean.
Preparation of bacterial liquid
1. Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118 was inoculated into LB solid medium and cultured at 37 ℃ for 12 hours (for activation).
2. And (3) inoculating the single colony obtained in the step (1) to 10mL of LB liquid culture medium, and culturing at 37 ℃ and 200rpm for 12h to obtain a bacterial liquid.
3. Adding LB liquid culture medium into the bacterial liquid obtained in the step 2 for dilution to obtain the bacterial liquid with the concentration of 108CFU/100g of bacterial liquid.
Second, pretreatment of bean curd
1. Cutting bean curd into blocks with length, width and height of 2-5cm, and oven drying in oven at 25-40 deg.C until water content is 55-65% to obtain dried bean curd block.
2. And (3) after the step (1) is finished, taking the dried bean curd blocks, and removing the bean curd blocks which are incomplete and/or uneven in color and/or high in moisture to obtain the selected bean curd blocks.
3. And (3) after the step 2 is finished, taking the selected bean curd blocks, cooking for 10-40min at the temperature of 121 ℃, and then cooling to 30-40 ℃ to obtain the unfermented bean curd blocks.
Thirdly, fermentation
Taking the unfermented bean curd block, inoculating the bacterial liquid obtained in the step one, wherein the inoculation amount is 108Mixing CFU/100g, fermenting and culturing at 40 deg.C for 48 hr to obtain fermented bean curd.
Analysis of active ingredients
1. Preparation of fermented bean curd lyophilized powder and unfermented bean curd lyophilized powder
Placing the unfermented bean curd in a refrigerator of-20 deg.C, freezing for 24 hr, transferring to a vacuum freeze drier (cold trap temperature is-48 deg.C to-60 deg.C), and freeze drying for 35-40 hr to obtain unfermented bean curd lyophilized powder.
Freezing the fermented bean curd in a refrigerator at-20 deg.C for 24 hr, transferring to a vacuum freeze drier (cold trap temperature is-48 deg.C to-60 deg.C), and freeze drying for 35-40 hr to obtain fermented bean curd lyophilized powder.
2. Mixing 1 volume part of fermented bean curd lyophilized powder and 5 volume parts of water, performing ultrasonic extraction for 3 times (ultrasonic parameters: 100W, 20min), centrifuging at 4000rpm for 10min, and collecting supernatant 1. Mixing 1 volume part of fermented bean curd lyophilized powder and 5 volume parts of 80% (v/v) methanol water solution, ultrasonic extracting for 3 times (ultrasonic parameters: 100W, 20min), centrifuging at 4000rpm for 10min, and collecting supernatant 2.
3. And (3) taking the supernatant 1, carrying out rotary steaming and concentration to obtain a fermented bean curd water extract, and further carrying out freeze drying to obtain the fermented bean curd water extract freeze-dried powder 1. And (3) taking the supernatant 2, carrying out rotary steaming and concentration to obtain a fermented bean curd alcohol extract, and further carrying out freeze drying to obtain the fermented bean curd alcohol extract freeze-dried powder 2.
And calculating the yield of the fermented bean curd water extract freeze-dried powder 1 and the fermented bean curd alcohol extract freeze-dried powder 2 according to a formula.
The yield (%) is the weight of the extract freeze-dried powder/the weight of the raw material freeze-dried powder x 100.
4. And (3) taking the freeze-dried powder of the water extract of the fermented bean curd or the freeze-dried powder of the alcohol extract of the fermented bean curd, and measuring the content of the polypeptide and the content of the total phenol.
According to the above steps, the fermented bean curd is replaced by unfermented bean curd, and other steps are not changed as a control.
The results are shown in Table 3.
TABLE 3 Total phenol content and polypeptide content of unfermented tofu and fermented tofu
Note: the difference of the shoulder mark letters (a, b, c) in the same row indicates that the difference is remarkable among groups, and p is less than 0.05; GAE, gallic acid equivalent.
The results show that compared with unfermented bean curd, the polypeptide content and the total phenol content in the aqueous extract of the fermented bean curd are respectively improved by 8.1 times and 2.7 times; the content of polypeptide and total phenol in the alcohol extract of fermented bean curd are respectively increased by 12.1 and 4.7 times.
Fifth, analysis of functional Activity
1. Preparation of aqueous extract and alcoholic extract of fermented bean curd
(1) Mixing 1 volume part of fermented bean curd lyophilized powder and 5 volume parts of water, performing ultrasonic extraction for 3 times (ultrasonic parameters: 100W, 20min), centrifuging at 4000rpm for 10min, and collecting supernatant 1. Mixing 1 volume part of fermented bean curd lyophilized powder and 5 volume parts of 80% (v/v) methanol water solution, ultrasonic extracting for 3 times (ultrasonic parameters: 100W, 20min), centrifuging at 4000rpm for 10min, and collecting supernatant 2.
(2) And (3) taking the supernatant 1, carrying out rotary steaming and concentration to obtain a fermented bean curd water extract, and further carrying out freeze drying to obtain the fermented bean curd water extract freeze-dried powder 1. And (3) taking the supernatant 2, carrying out rotary steaming and concentration to obtain a fermented bean curd alcohol extract, and further carrying out freeze drying to obtain the fermented bean curd alcohol extract freeze-dried powder 2.
According to the steps, the fermented bean curd is replaced by unfermented bean curd, and other steps are not changed, so that the unfermented bean curd water extract freeze-dried powder and the unfermented bean curd alcohol extract freeze-dried powder are obtained.
2. Antithrombotic activity of fermented bean curd
The antithrombotic activity is mainly reflected in fibrinolytic enzyme activity and anticoagulant activity.
And (3) detecting the plasmin activity and the anticoagulant activity of a sample to be detected (the freeze-dried powder of the fermented bean curd water extract, the freeze-dried powder of the fermented bean curd alcohol extract, the freeze-dried powder of the unfermented bean curd water extract or the freeze-dried powder of the unfermented bean curd alcohol extract).
The results are shown in Table 4. The result shows that compared with the non-fermented bean curd, the fibrinolytic enzyme activity and the anticoagulation activity in the fermented bean curd are both obviously improved, the fibrinolytic enzyme activity and the anticoagulation activity of the aqueous extract of the fermented bean curd are the strongest, which are 296.1FU/g and 0.04mg/mL respectively, and the anticoagulation effect of the aqueous extract of the fermented bean curd is superior to that of positive control heparin sodium, which indicates that the fermented bean curd has higher antithrombotic activity.
TABLE 4 functional Activity of unfermented and fermented tofu
Note: the difference of the shoulder mark letters (a, b, c) in the same row indicates that the difference is remarkable among groups, and p is less than 0.05; positive control: heparin sodium (0.55 +/-0.06), huperzine A (0.06 +/-0.01), captopril (0.000002 +/-0.000) and acarbose (0.18 +/-0.03); ACHE, acetylcholinesterase; ACE, angiotensin converting enzyme.
3. Acetylcholinesterase inhibitory activity of fermented bean curd
The acetylcholinesterase inhibitory activity of the sample to be tested (lyophilized powder of fermented soybean curd aqueous extract, lyophilized powder of unfermented soybean curd aqueous extract or huperzine A) was measured according to the method described in the literature (Liu, Y.Q., Wang, L.J., Cheng, Y.Q., Saito, M., Yamaki, K., & Qiao, Z.H., et al (2009). Huperzine A is used as positive control.
The results are shown in Table 4. The results show that the acetylcholinesterase inhibition activity of the aqueous extract and the alcohol extract of the fermented bean curd is obviously higher than that of the unfermented bean curd. The acetylcholinesterase inhibitory activity of the fermented bean curd alcohol extract is 2.14mg/mL most strongly.
The above results indicate that the fermented bean curd has a stronger acetylcholinesterase inhibitory effect.
4. Blood pressure lowering effect of fermented bean curd
Angiotensin converting enzyme inhibition of samples to be tested (lyophilized fermented bean curd water extract powder, lyophilized unfermented bean curd alcohol extract powder or captopril) was tested according to the method described in literature (Zhang, b., Sun, q., Liu, h.j., Li, s.z., & Jiang, Z.Q. (2017.) Characterization of action from Chinese chicken kit primers and inhibitors in medium termination and production of enzyme i-converting enzyme (ace). Captopril was the positive control.
The results are shown in Table 4. The result shows that the angiotensin converting enzyme inhibition rate of the aqueous extract and the alcohol extract of the fermented bean curd is obviously higher than that of the unfermented bean curd. The angiotensin converting enzyme inhibition rate of the fermented bean curd alcohol extract is 0.63mg/mL most strongly.
The above results indicate that the fermented bean curd has a stronger blood pressure lowering effect.
5. Hypoglycemic effect of fermented bean curd
The inhibition ratio of α -glucosidase in the sample to be tested (freeze-dried powder of fermented bean curd extract, freeze-dried powder of non-fermented bean curd extract or acarbose) was determined as a positive Control according to the method described in the literature (Shukla, s., Park, j., Kim, d.h., Hong, s.y., Lee, j.s., & Kim, M. (2016.). Total phenolic content, antioxidant, tyrosinase and α -glucosidase inhibitors in the publications of water soluble extracts of non-fermented starter culture doenjang, a korean transferred sol bean curd sample variation.food Control, 59, 854-kava 861.).
The experimental results are shown in Table 4, and the results show that the inhibition rates of α -glucosidase of the fermented bean curd aqueous extract and the fermented bean curd alcohol extract are obviously higher than that of unfermented bean curd, and the inhibition rate of α -glucosidase of the fermented bean curd alcohol extract is strongest and is 4.07 mg/mL.
The results show that the fermented bean curd has stronger blood sugar reducing effect.
<110> university of agriculture in China
<120> preparation method of fermentation product with multiple physiological function activities and special bacillus amyloliquefaciens thereof
<160>1
<170>PatentIn version 3.5
<210>1
<211>1352
<212>DNA
<213> Bacillus amyloliquefaciens (Bacillus amyloliquefaciens)
<400>1
tgagtaacac gtgggtaacc tgcctgtaag actgggataa ctccgggaaa ccggggctaa 60
taccggatgc ttgtttgaac cgcatggttc aaacataaaa ggtggcttcg gctaccactt 120
acagatggac ccgcggcgca ttagctagtt ggtgaggtaa cggctcacca aggcgacgat 180
gcgtagccga cctgagaggg tgatcggcca cactgggact gagacacggc ccagactcct 240
acgggaggca gcagtaggga atcttccgca atggacgaaa gtctgacgga gcaacgccgc 300
gtgagtgatg aaggttttcg gatcgtaaag ctctgttgtt agggaagaac aagtgccgtt 360
caaatagggc ggcaccttga cggtacctaa ccagaaagcc acggctaact acgtgccagc 420
agccgcggta atacgtaggt ggcaagcgtt gtccggaatt attgggcgta aagggctcgc 480
aggcggtttc ttaagtctga tgtgaaagcc cccggctcaa ccggggaggg tcattggaaa 540
ctggggaact tgagtgcaga agaggagagt ggaattccac gtgtagcggt gaaatgcgta 600
gagatgtgga ggaacaccag tggcgaaggc gactctctgg tctgtaactg acgctgagga 660
gcgaaagcgt ggggagcgaa caggattaga taccctggta gtccacgccg taaacgatga 720
gtgctaagtg ttagggggtt tccgcccctt agtgctgcag ctaacgcatt aagcactccg 780
cctggggagt acggtcgcaa gactgaaact caaaggaatt gacgggggcc cgcacaagcg 840
gtggagcatg tggtttaatt cgaagcaacg cgaagaacct taccaggtct tgacatcctc 900
tgacaatcct agagatagga cgtccccttc gggggcagag tgacaggtgg tgcatggttg 960
tcgtcagctc gtgtcgtgag atgttgggtt aagtcccgca acgagcgcaa cccttgatct 1020
tagttgccag cattcagttg ggcactctaa ggtgactgcc ggtgacaaac cggaggaagg 1080
tggggatgac gtcaaatcat catgcccctt atgacctggg ctacacacgt gctacaatgg 1140
gcagaacaaa gggcagcgaa accgcgaggt taagccaatc ccacaaatct gttctcagtt 1200
cggatcgcag tctgcaactc gactgcgtga agctggaatc gctagtaatc gcggatcagc 1260
atgccgcggt gaatacgttc ccgggccttg tacacaccgc ccgtcacacc acgagagttt 1320
gtaacacccg aagtcggtga ggtaaccttt tt 1352
Claims (10)
1. Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118, the preservation number of which in China general microbiological culture Collection center is CGMCC No. 16050.
2. A microbial inoculum, which is characterized in that: the microbial inoculum contains the bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118CGMCC No.16050 in claim 1.
3. The use of Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118CGMCCNo.16050 or the microbial inoculum according to claim 2) in at least one of A) fermentation culture of red bean, A) preparation of a product with fibrinolytic enzyme activity, A) preparation of a product with anticoagulant activity, A) preparation of a product with hypoglycemic function, A) preparation of a product with antioxidant activity, A) preparation of a product for eliminating DPPH free radicals, A) preparation of a product for eliminating ABTS free radicals, A) preparation of a product for improving FRAP reducing power, A) preparation of a product for improving glucosidase inhibiting power, A) preparation of a product for improving DPP-IV inhibiting power, A) preparation of a product for improving angiotensin converting enzyme inhibiting power, A) preparation of a product for improving acetylcholine esterase inhibiting power, A) preparation of product for improving total phenol content, A) preparation of product for improving flavone content, A) preparation of product for improving angiotensin converting enzyme inhibiting power, A) preparation of product for improving angiotensin converting enzyme inhibiting enzyme content, A) preparation of product for improving angiotensin converting enzyme A) and/or improving content of SOD, A) and/or preventing hypertension, A) treating or treating diabetes mellitus, and/or treating hypertension, and/or preventing hypertension, A) and/or treating hypertension, A) or preventing hypertension, A) and/or treating hypertension, and/or treating or preventing hypertension, and/or treating a high content of a cardiovascular diseases.
4. Use according to claim 3, characterized in that: the product is fermented small red beans prepared by the method of any one of claims 5 to 9.
5. A process for preparing fermented red bean includes inoculating Bacillus amyloliquefaciens to aseptic red bean, fermenting to obtain fermented red bean, and increasing the fibrinolytic activity, anticoagulant activity, antioxidizing activity, DPPH free radical eliminating rate, ABTS free radical eliminating rate, FRAP reducing power, α -glucosidase inhibiting rate, DPP-IV inhibiting rate, total phenol content, flavone content and polypeptide content and SOD enzyme content.
6. The method of claim 5, wherein: the preparation method of the sterile small red beans comprises the following steps: soaking semen Phaseoli in water, and steaming for 20-40 min.
7. A method for preparing fermented bean curd comprises inoculating Bacillus amyloliquefaciens into sterile bean curd, and fermenting to obtain fermented bean curd, wherein compared with the sterile bean curd, the fermented bean curd has improved fibrinolytic enzyme activity and/or anticoagulant activity and/or acetylcholinesterase inhibition rate and/or angiotensin converting enzyme inhibition rate and/or α -glucosidase inhibition rate and/or total phenol content and/or polypeptide content.
8. The method of claim 7, wherein: the steps for preparing the sterile bean curd are as follows: oven drying bean curd, and steaming for 10-40 min.
9. The method of any of claims 5 to 8, wherein: the Bacillus amyloliquefaciens is the Bacillus amyloliquefaciens (Bacillus amyloliquefaciens) CAUNDJ118CGMCC No.16050 in claim 1.
10, K1) or K2):
K1) use of fermented red bean prepared by the method according to claim 5 or 6, which is at least one of A22), A22) and A22), for producing plasmin A22), for anticoagulation A22), for lowering blood glucose, A22) for antioxidation, A22) for scavenging DPPH radicals, A22) for scavenging ABTS radicals, A22) for increasing FRAP reducing power, A22) for increasing 22-glucosidase inhibition, A22) for increasing DPP-IV inhibition, A22) for increasing total phenol content, A22) for increasing flavone content, A22) for increasing polypeptide content, A22) for increasing SOD content, A22) for preventing and/or treating cardiovascular diseases and/or treating diabetes mellitus;
K2) the fermented bean curd prepared by the method according to claim 7 or 8 is at least one of A22), A23), A24), A29), A31), A32), A33), A35), A37), A38), A39), 40), 41) and A43), wherein A22) produces plasmin, A23) anticoagulation, A24) reduces blood sugar, A29) increases α -glucosidase inhibition rate, A31) increases angiotensin converting enzyme inhibition rate, A32) increases acetylcholinesterase inhibition rate, A33) increases total phenol content, A35) increases polypeptide content, A37) prevents and/or treats cardiovascular and cerebrovascular diseases, A38) prevents and/or treats thrombotic diseases, A39) prevents and/or treats diabetes, 40) prevents and/or treats hypertension, 41) and/or treats senile dementia, and A43) reduces dementia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811195573.9A CN111040958B (en) | 2018-10-15 | 2018-10-15 | Preparation method of fermentation product with multiple physiological function activities and special bacillus amyloliquefaciens thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811195573.9A CN111040958B (en) | 2018-10-15 | 2018-10-15 | Preparation method of fermentation product with multiple physiological function activities and special bacillus amyloliquefaciens thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111040958A true CN111040958A (en) | 2020-04-21 |
CN111040958B CN111040958B (en) | 2022-02-01 |
Family
ID=70230042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811195573.9A Active CN111040958B (en) | 2018-10-15 | 2018-10-15 | Preparation method of fermentation product with multiple physiological function activities and special bacillus amyloliquefaciens thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111040958B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114712485A (en) * | 2022-01-27 | 2022-07-08 | 南京农业大学 | Application of lipopeptide surfactin in preventing or relieving type II diabetes |
CN117534731A (en) * | 2021-09-24 | 2024-02-09 | 江西康之康中药科技有限公司 | Anticoagulant peptide and application thereof in anticoagulant products |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102533576A (en) * | 2010-12-08 | 2012-07-04 | 中国科学院过程工程研究所 | Bacillus amyloliquefaciens LSSE-62 and application thereof |
CN107043719A (en) * | 2017-03-16 | 2017-08-15 | 河北省农林科学院植物保护研究所 | Bacillus amyloliquefaciens HMB28353 and its application |
-
2018
- 2018-10-15 CN CN201811195573.9A patent/CN111040958B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102533576A (en) * | 2010-12-08 | 2012-07-04 | 中国科学院过程工程研究所 | Bacillus amyloliquefaciens LSSE-62 and application thereof |
CN107043719A (en) * | 2017-03-16 | 2017-08-15 | 河北省农林科学院植物保护研究所 | Bacillus amyloliquefaciens HMB28353 and its application |
Non-Patent Citations (1)
Title |
---|
方元元等: "Bacillus amyloliquefaciens SY07产α-葡萄糖苷酶抑制剂液态发酵条件优化", 《中国调味品》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117534731A (en) * | 2021-09-24 | 2024-02-09 | 江西康之康中药科技有限公司 | Anticoagulant peptide and application thereof in anticoagulant products |
CN114712485A (en) * | 2022-01-27 | 2022-07-08 | 南京农业大学 | Application of lipopeptide surfactin in preventing or relieving type II diabetes |
Also Published As
Publication number | Publication date |
---|---|
CN111040958B (en) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102533576B (en) | Bacillus amyloliquefaciens LSSE-62 and application thereof | |
CN110862947B (en) | Bacillus safensis, microbial agent, application and vinegar preparation method | |
CN103243040B (en) | Bacillus subtilis LSSE-22 and application thereof | |
US12012590B2 (en) | Bacillus velezensis, culture method therefor and application thereof | |
CN103333828B (en) | Application of anti-mildew bacillus strain and antimicrobial product thereof in corn storage | |
CN103695341B (en) | A kind of algin catenase secreted by marine bacteria and preparation method thereof | |
CN110777089B (en) | Strain for high-yield nattokinase and method for preparing natto by using strain | |
CN111826295A (en) | Bacillus belgii strain for fermenting soybean meal | |
CN111040958B (en) | Preparation method of fermentation product with multiple physiological function activities and special bacillus amyloliquefaciens thereof | |
CN107841473A (en) | A kind of bacillus subtilis of high-yield nattokinase and its application | |
CN102925361B (en) | AFB1 degrading bacterium and degrading enzyme | |
CN107129944B (en) | Bacillus belgii strain for producing nattokinase and application thereof | |
CN103773712A (en) | Antifungal peptide high-yield strain and method for preparing antibacterial peptide | |
CN111647517A (en) | Candida rugosa strain producing protease | |
CN105670936B (en) | A kind of method of Trametes trogii bacterial strain and its application and Pu'er tea processing | |
Long et al. | Isolation of Bacillus spp. with high fibrinolytic activity and performance evaluation in fermented douchi | |
CN114644995B (en) | Bacillus amyloliquefaciens for preventing and controlling aflatoxin B1 pollution and application thereof | |
CN101906391B (en) | S.thermophilus grx90 for fermenting soya-bean milk products and application thereof | |
CN114517172A (en) | Staphylococcus equisimilis and application thereof in preventing and treating gray mold of fruits and vegetables | |
CN103865865B (en) | A kind of sea cucumber enteron aisle produces Sumizyme MP bacterial strain and application thereof | |
CN112708585A (en) | Bacillus licheniformis strain for high yield of plasmin and gamma-PGA and application thereof | |
CN104894020B (en) | A kind of protease and its production bacterial strain | |
CN106544294A (en) | A kind of bacillus subtilises H 9 and its application | |
CN105982035A (en) | Natto preparing method for increasing inhibition ratio of natto water extract to alpha-glucosidase | |
CN104830718A (en) | Processing method of S-8 bacterium and soybean anti-nutritional factor inactivated by same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |